Publication Topic

Gillezeau C, Movva N, Fryzek J, Rabon-Stith K, Brohawn PZ, Gerwen M van, Taioli E. Molecular epidemiology study of interferon gamma (IFN-γ) expression in urothelial bladder cancer (UBC). Poster presentation [preview] at 37^th ICPE (International Conference on Pharmacoepidemiology & Therapeutic Rick Management), virtual conference, August 2021.

Bylsma L, Nielson C, Fryzek J, Saad H, Crawford J. Edit chemotherapy relative dose intensity, overall survival, and hematologic toxicity in solid-tumor cancer patients: A literature review and meta-analysis. Poster presentation [preview] at 37^th ICPE (International Conference on Pharmacoepidemiology & Therapeutic Rick Management), Virtual, August 2021.

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. 2020. J Cancer Edu 35(1):178–186.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478.

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882.

Dronin-Fenton D, Dalvi T, Movva N, Pedersen I, Hansen H, Fryzek J, Mellemgaard A, Rasmussen T, Klein A, Hamilton-Dutoit S, Nørgaard M. PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark. Accepted for presentation to a virtual meeting (due to COVID-19) of the European Society for Medical Oncology (ESMO), abstract #2865, August 2020.